VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 7, 2026

Stock Comparison

Brookfield Corporation vs Pfizer Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Brookfield Corporation

BN · New York Stock Exchange

Market cap (USD)$109.6B
Gross margin (TTM)34.5%
Operating margin (TTM)24.1%
Net margin (TTM)1.3%
SectorFinancials
IndustryAsset Management
CountryCA
Data as of2026-01-05
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Brookfield Corporation's moat claims, evidence, and risks.

View BN analysis

Pfizer Inc.

PFE · New York Stock Exchange

Market cap (USD)$143.1B
Gross margin (TTM)71.2%
Operating margin (TTM)27.8%
Net margin (TTM)15.6%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2025-12-29
Moat score
58/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Pfizer Inc.'s moat claims, evidence, and risks.

View PFE analysis

Comparison highlights

  • Moat score gap: Brookfield Corporation leads (65 / 100 vs 58 / 100 for Pfizer Inc.).
  • Segment focus: Brookfield Corporation has 6 segments; Pfizer Inc. has 5 segments (47.4% in Primary Care).
  • Moat breadth: Brookfield Corporation has 10 moat types across 5 domains; Pfizer Inc. has 8 across 3.

Primary market context

Brookfield Corporation

Asset Management

Market

Alternative asset management (private markets: infrastructure, renewables, private equity, real estate, credit)

Geography

Global

Customer

Institutional investors and private wealth channels

Role

General partner (GP) / asset manager

Pfizer Inc.

Primary Care

Market

Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)

Geography

Global

Customer

Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement

Role

Innovator biopharma (R&D + manufacturing + commercialization)

Revenue share

47.4%

Side-by-side metrics

Brookfield Corporation
Pfizer Inc.
Ticker / Exchange
BN - New York Stock Exchange
PFE - New York Stock Exchange
Market cap (USD)
$109.6B
$143.1B
Gross margin (TTM)
34.5%
71.2%
Operating margin (TTM)
24.1%
27.8%
Net margin (TTM)
1.3%
15.6%
Sector
Financials
Healthcare
Industry
Asset Management
Drug Manufacturers - General
HQ country
CA
US
Primary segment
Asset Management
Primary Care
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
65 / 100
58 / 100
Moat domains
Demand, Network, Financial, Supply, Legal
Legal, Demand, Supply
Last update
2026-01-05
2025-12-29

Moat coverage

Shared moat types

Long Term ContractsCapex Knowhow ScaleOperational Excellence

Brookfield Corporation strengths

Ecosystem ComplementsBrand TrustFloat PrepaymentCost Of Capital AdvantagePermits Rights Of WayPhysical Network DensityGeographic Natural

Pfizer Inc. strengths

IP Choke PointProcurement InertiaGovernment Contracting RelationshipsCompliance AdvantageEmbedded R&D partnership platform

Segment mix

Brookfield Corporation segments

Full profile >

Asset Management

Oligopoly

n/a

Wealth Solutions (Insurance)

Competitive

n/a

Renewable Power and Transition

Competitive

n/a

Infrastructure

Oligopoly

n/a

Private Equity (Operating Businesses)

Competitive

n/a

Real Estate

Competitive

n/a

Pfizer Inc. segments

Full profile >

Primary Care

Oligopoly

47.4%

Specialty Care

Oligopoly

26.2%

Oncology

Competitive

24.5%

Pfizer CentreOne

Competitive

1.8%

Pfizer Ignite

Competitive

0.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.